Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis

Celldex Therapeutics, Inc. has announced that the first patient has been dosed in their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). EoE is a chronic inflammatory disease of the esophagus and the most common type of eosinophilic gastrointestinal disease. The study aims to evaluate the efficacy and safety profile of subcutaneous barzolvolimab in patients with active EoE. The ..